Friday, February 22, 2019
LAS VEGAS, Feb. 21, 2019 /PRNewswire/ -- GNCC Capital, Inc. (OTC: GNCP) ("The Company" or "GNCC") announces that it has acquired a 100% interest in BioCann Pharma S.A.S. ("BioCann"), a Cannabis CBD Pharmaceutical Grade Oils Producer and Distributor, incorporated in and operating in the Republic of Colombia ("Colombia") and with offices in Burlington, Ontario, Canada.
A brief description of the business of BioCann:
BioCann sources the Cannabis a/k/a Biomass from Licensed Growers in Colombia and in the Cundinamarca, Valle del Cauca and Antioquia regions and from those whom grow the strains with the highest quality standard as is required by BioCann. BioCann processes the Cannabis a/k/a Biomass through its Joint Venture/Partnership Agreement with a licensed processing and manufacturing facility which is GMP Certified and complies with EU Pharmacopoeia Standards. This facility with the necessary Laboratories, located in Bogota, Colombia, complete with the necessary Laboratories and where it extracts the CBD Oil isolate and in pharmaceutical grade and as are required by BioCann. This entire process assures that BioCann is as consistent as possible from batch to batch in order to produce replicable results.
BioCann generates its revenues and profits through the bulk sale of these various Pharmaceutical Grade CBD Oils through distribution channels in Colombia and throughout Latin America. It is noted that neither BioCann, it's Partners and Joint Venture Associates do not operate in, nor sell or market any products in the USA due to Federal Laws prohibiting the same.
Salient Points of this transaction:
Given the sheer amount of information required by our shareholders, we have prepared an extensive OTCIQ Filing complete with Exhibits in order to set out each and every detail of this transaction. We encourage our shareholders to read the same and prior to any dealings in our shares in the open market. A link to this OTCIQ Filing made today: https://backend.otcmarkets.com/otcapi/company/financial-report/212241/content
Your Directors are particularly gratified by the long term view being undertaken by BioCann, their commitment to the achievement of Net Revenue Projections, extensive stock restrictions, all of this being coupled with their contractual performance warranties and penalties for any underperformance resulting on their Projected Net Revenues.
Forward-Looking Statements:-
This press release may contain forward-looking statements. The words "believe," "expect," "should," "intend," "estimate," "projects," variations of such words and similar expressions identify forward-looking statements, but their absence does not mean that a statement is not a forward-looking statement. These forward-looking statements are based upon the Company's current expectations and are subject to a number of risks, uncertainties and assumptions. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.
View original content:http://www.prnewswire.com/news-releases/gncc-capital-inc-acquires-biocann-pharma-sas-300799508.html
SOURCE GNCC Capital, Inc.